Trimovax

Active immunization against infection by measles, mumps and rubella

IM or SC Active immunisation against measles, mumps and rubella 19-49 years old: 0.5 mL SC; second dose may be administered 28 days apart >50 years old: 0.5 mL SC; administer 1 dose only 2nd dose recommendations Student in postsecondary eduction Recent exposure Occupational risk Previously vaccinated with killed measles vaccine Vaccinated with unknown type of measles vaccine during 1963-67 International travelers Healthcare personnel should consider receiving 2 doses of MMR vaccine at the appropriate interval for measles and mumps or 1 dose of MMR vaccine for rubella Immunization in Pregnancy Pregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health-care facility Pregnancy should be avoided for 28 days following vaccine administration

IM or SC Active immunisation against measles, mumps and rubella Routine vaccination: First dose of 0.5 mL SC between age 12-15 months; administer second dose between 4-6 yr. But may be administered during any visit provided that at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not received the second dose previously should complete the schedule by the visit at age 11–12 years. Ensure all school-aged children and adolescents received 2 doses (0.5 mL SC each) Minimum time between 1st and 2nd dose is 4 wk

Current febrile respiratory illness or other febrile infection. Patients receiving immunosuppressive therapy; primary and acquired immunodeficiency states. Blood dyscrasias, cancers affecting the bone marrow or lymphatic systems. Pregnancy. Active untreated tuberculosis.

Live, attenuated viruses stimulate active immunity to disease caused by measles, rubella, and mumps viruses.

Patients with history of cerebral injury or seizures. Patients with thrombocytopenia and those who develop thrombocytopenia after 1st dose. For patients with active tuberculosis, tuberculosis treatment should be started before using the vaccine. Vaccination may be deferred in patients with moderate or severe acute illness. Pregnancy should be avoided for 28 days after vaccination. Lactation. Lactation: Uot known if measles and mumps excreted in breast milk; rubella is excreted in milk; use caution

Fever,Syncope,Ataxia,Pain at site,Headache,Rash,Lymphadenopathy,Myalgia,Stevens-Johnson syndrome,Thrombocytopenia,Optic neuritis,Encephalitis,Malaise,Irritability,Guillain-Barre synd,Subacute sclerosing panencephalitis (rare),Seizures,Parotitis,Bronchospasm,Leukocytosis,Conjunctivitis,Otitis media,Nerve deafness

Immune globulins may reduce the efficacy of vaccines. May reduce the diagnostic effect of tuberculin tests. Potentially Fatal: Concurrent use with immunosuppressants may increase the adverse effects of vaccines; may also reduce the efficacy of vaccines.